key: cord-0991775-dl30tip0
authors: Alfi, Or; Hamdan, Marah; Wald, Ori; Yakirevitch, Arkadi; Wandel, Ori; Oiknine-Djian, Esther; Gvili, Ben; Knoller, Hadas; Rozendorn, Noa; Golan, Hadar; Adar, Sheera; Vorontsov, Olesya; Mandelboim, Michal; Zakay-Rones, Zichria; Oberbaum, Menachem; Panet, Amos; Wolf, Dana G.
title: SARS-CoV-2 Omicron is specifically restricted in its replication in human lung tissue, compared to other variants of concern
date: 2022-03-31
journal: bioRxiv
DOI: 10.1101/2022.03.31.486531
sha: c6e29b6f852999abf718ba986c9e865018465663
doc_id: 991775
cord_uid: dl30tip0

SARS-CoV-2 Omicron variant has been characterized by decreased clinical severity, raising the question of whether early variant-specific interactions within the mucosal surfaces of the respiratory tract could mediate its attenuated pathogenicity. Here, we employed ex vivo infection of native human nasal and lung tissues to investigate the local-mucosal susceptibility and innate immune response to Omicron, compared to Delta and earlier SARS-CoV-2 variants of concern (VOC). We show that the replication of Omicron in lung tissues is highly restricted compared to other VOC, whereas it remains relatively unchanged in nasal tissues. Mechanistically, Omicron induced a much stronger antiviral interferon response in infected tissues compared to Delta and earlier VOC - a difference which was most striking in the lung tissues, where the innate immune response to all other SARS-CoV-2 VOC was blunted. Our data provide new insights to the reduced lung involvement and clinical severity of Omicron.

respiratory tract could mediate its attenuated pathogenicity. Here, we employed ex vivo 27 infection of native human nasal and lung tissues to investigate the local-mucosal 28 susceptibility and innate immune response to Omicron, compared to Delta and earlier SARS- 29 CoV-2 variants of concern (VOC). We show that the replication of Omicron in lung tissues is 30 highly restricted compared to other VOC, whereas it remains relatively unchanged in nasal The recently evolved SARS-CoV-2 Omicron variant has been shown to exhibit increased 43 transmissibility and escape from humoral immunity generated by previous infections and 44 vaccines 1-3 . Importantly, accumulating clinical-epidemiological observations have 45 demonstrated that Omicron is associated with milder disease compared with Delta and earlier 46 variants of concern (VOC) 2,4,5 . The decreased clinical severity of Omicron has been partly 47 attributed to the presence of pre-existing population immunity 2 . Additionally, it has been 48 proposed that intrinsic viral factors could play a part in its milder disease course. This notion 49 was suggested by studies in animal models showing that Omicron infection caused milder 50 lung pathology 6-8 , and by the reported inefficient replication of Omicron in human alveolar 51 organoids and ex vivo infected lung tissues 9, 10 . It has been shown that Omicron enters cells 52 by a different route than other variants and does not spread as efficiently by fusion, thereby 53 limiting viral infection in the lungs, where cell-fusion plays a role in viral transmission 2,9-12 . 54 These studies highlight the multifactorial yet incompletely resolved mechanisms underlying 55 the decreased pathogenicity of Omicron.

The innate immune response is known to play a key-role in SARS-CoV-2 infection 57 severity [13] [14] [15] . We therefore reasoned that the early innate immune responses to Omicron 58 within the respiratory tract could potentially mediate its milder clinical severity. To 68 Nasal and lung tissues maintained viable as integral organ cultures as described 16 Omicron elicits enhanced antiviral interferon response in human respiratory tissues 94 We have previously shown that SARS-CoV-2 infection (the ancestral isolate USA-95 WA1/2020) induced a robust innate immune response in nasal tissues, albeit a highly Delta) 2, 9, 11, 12 , which could lead to early activation of unique endosomal Toll-like receptors. 161 The mechanism by which Omicron triggers the enhanced interferon response in human 162 respiratory tissues remains to be elucidated.

Our study has several limitations. Native respiratory tissues in organ culture are relatively 

Omicron extensively but incompletely escapes Pfizer BNT162b2 270 neutralization

Milder disease with Omicron: is it the virus or the pre-existing immunity

Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA 274 vaccine-elicited human sera

Early assessment of the clinical severity of the SARS-CoV-2 omicron 276 variant in South Africa: a data linkage study

SARS-CoV-2 variants of concern and variants under 278 investigation in England

Reduced pathogenicity of the SARS-CoV-2 Omicron

SARS-CoV-2 Omicron-B.1.1.529 Variant leads to less severe 282

disease than Pango B and Delta variants strains in a mouse model of severe COVID-283

The omicron (B.1.1.529) SARS-CoV-2 variant of concern does 285 not readily infect Syrian hamsters

SARS-CoV-2 Omicron efficiently infects human airway

SARS-CoV-2 Omicron variant replication in human bronchus and 289 lung ex vivo

The hyper-transmissible SARS-CoV-2 Omicron variant exhibits 291

significant antigenic change, vaccine escape and a switch in cell entry mechanism

The SARS-CoV-2 variant, Omicron, shows rapid replication in 294

human primary nasal epithelial cultures and efficiently uses the endosomal route of 295

from cells to organisms

Impaired local intrinsic immunity to SARS-CoV-2 infection in 300 severe COVID-19

The interferon landscape along the respiratory tract impacts the 302 severity of COVID-19

Human Nasal and Lung Tissues Infected Ex Vivo with SARS-CoV-2 304

Provide Insights into Differential Tissue-Specific and Virus-Specific Innate Immune 305

Responses in the Upper and Lower Respiratory Tract

Functional Landscape of SARS-CoV-2 Cellular Restriction

Interferon-λ Mediates Non-redundant Front-Line Antiviral 309

Protection against Influenza Virus Infection without Compromising Host Fitness